GLP-1 medicines have transformed weight management. Originally developed for type 2 diabetes, these medications are now widely used for obesity because of their strong effects on appetite and body weight.
But with multiple options available, semaglutide, liraglutide, and tirzepatide, the big question is: Which GLP-1 works best for weight loss?
Let’s look at what science says.
How Do GLP-1 Medicines Help With Weight Loss?
GLP-1 receptor agonists mimic a natural hormone called glucagon-like peptide-1.
According to the National Institutes of Health (NIH) and Mayo Clinic, GLP-1 medicines help with weight loss by reducing appetite, increasing feelings of fullness, slowing stomach emptying, and lowering food cravings.
This leads to lower calorie intake over time without forcing restrictive dieting.
- Semaglutide (Wegovy Dose)
Approved for: Chronic weight management
Form: Weekly injection
Semaglutide (brand name Wegovy for weight loss) has shown some of the strongest weight-loss results among GLP-1 medicines.
In the STEP clinical trials published in The New England Journal of Medicine:
- Participants lost an average of ~15% of their body weight
- Some individuals lost 20% or more
- Results were seen when combined with lifestyle changes
This is significantly higher than earlier GLP-1 medicines. Because of this evidence, semaglutide is currently considered one of the most effective GLP-1 options specifically approved for obesity.
- Tirzepatide (Mounjaro/Zepbound in some regions)
- Approved for: Type 2 diabetes (weight indications expanding in some regions)
- Form: Weekly injection
Tirzepatide is slightly different. It is not just a GLP-1 agonist; it activates both GLP-1 and GIP (another metabolic hormone).
In the SURPASS and SURMOUNT trials published:
- Average weight loss reached ~20% or more in higher-dose groups
- Some participants approached surgical-level weight reduction
This suggests tirzepatide may produce greater average weight loss compared to semaglutide in certain populations. However, it is newer and long-term real-world data is still expanding.
- Liraglutide (Saxenda)
- Approved for: Weight management
- Form: Daily injection
Liraglutide was one of the first GLP-1 medicines approved for obesity.
Clinical studies show:
- Average weight loss is around 5-8%
- Requires daily injections
Compared to semaglutide and tirzepatide, weight loss is generally more modest.
So, Which One Is ‘Best’?
Based on published trial data:
- Tirzepatide: Highest average weight loss in trials
- Semaglutide (Wegovy dose): Strong, well-established weight loss results
- Liraglutide (Saxenda): Moderate weight loss
But ‘best’ depends on:
- Medical history
- Tolerability
- Side effects
- Cost and availability
- Doctor supervision
Weight loss results also vary significantly from person to person.
What About Oral GLP-1 Medicines?
Currently, the only widely available oral GLP-1 medicine is oral semaglutide (Rybelsus), which is approved for diabetes, not specifically for weight loss.
Weight reduction with oral semaglutide tends to be modest compared to higher-dose injectable semaglutide used for obesity.
The Future of Weight Loss: Oral GLP-1 Innovations
One major limitation of current high-efficacy GLP-1 medicines is that they require injections. This has led to growing interest in next-generation oral GLP-1 therapies.
According to the Zydus development overview, ZYOG1 is a novel orally administered GLP-1 receptor agonist being developed for both type 2 diabetes and obesity.
While large-scale human clinical trial data are still awaited publicly, the development goal is to:
- Provide oral (non-injectable) GLP-1 therapy
- Support glucose control and weight management
- Potentially improve tolerability
If future trials confirm strong weight-loss outcomes, next-generation oral GLP-1 medicines like ZYOG1 could expand access for individuals who prefer tablets over injections.
However, until peer-reviewed phase 3 data are available, injectable semaglutide and tirzepatide currently have the strongest published evidence for weight reduction.
Side Effects to Consider
According to NIH and Mayo Clinic, common GLP-1 side effects include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
These often improve over time but can limit tolerability for some individuals. Rare risks include pancreatitis and thyroid-related concerns in specific populations. These medicines are not recommended during pregnancy.
Final Answer: Which GLP-1 Is Best for Weight Loss?
Based on current published evidence:
- Tirzepatide shows the highest average weight loss in clinical trials.
- Semaglutide (Wegovy dose) has strong, well-established results and broad approval.
- Liraglutide produces more modest weight reduction.
- Oral GLP-1 options are emerging, but injectable forms currently show stronger weight-loss data.
The ‘best’ GLP-1 depends on individual health goals, medical history, and doctor guidance. As research progresses, including the development of investigational oral GLP-1 medicines like ZYOG1, treatment options for weight management may become both more effective and more convenient.
